Epilepsy Research
Volume 26, Issue 1 , Pages 295-304, December 1996

Kindling with clozapine: behavioral and molecular consequences

  • J.R. Stevens

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 (503) 678-1524; fax: +1 (503) 678-3216.
    • Departments of Neurology and Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
  • ,
  • D. Denney

      Affiliations

    • Departments of Neurology and Psychiatry, Oregon Health Sciences University, Portland, OR 97201, USA
  • ,
  • P. Szot

      Affiliations

    • Geriatric Research, Education and Clinical Center (GRECC), Veterans Affairs Medical Center, Seattle, WA 98108, USA
    • Department of Psychiatry and Behavioral Science, University of Washington, Seattle, WA 98195, USA

Received 22 October 1995; accepted 5 December 1995.

Abstract 

Clozapine is an ‘atypical’ neuroleptic that improves symptoms of many patients with schizophrenia whose illness is resistant to treatment with other neuroloptics. Unlike the ‘typical’ neuroleptics (chlorpromazine, haloperidol), clozapine does not induce extrapyramidal symptoms such as Parkinsonism and tardive dyskinesia in humans or catalepsy in the rat. However, clozepine frequently causes epileptiform EEG changes and causes seizures in 3–5% of patients treated with this drug in therapeutic doses. Clozapine also induces dose dependent myoclonus in the partially restrained rat. In the experiments reported here, partially restrained rats were administered repeated alternate day or weekly low, fixed doses of clozapine (1 mg/kg). This dose initially caused no behavioral change. Following the third and subsequent administrations, the same dose elicited an increasing number of myoclonic seizure-like jerks reaching 140/h following the 15th injection in rats receiving the same low dose of clozapine on alternate days and 160/h following the 9th injection in animals that received the same dose once weekly. These effects are consistent with kindling, i.e. a progressive increase of brain excitability following repeated administration of a fixed subconvulsive dose of an excitatory agent. Clozapine kindled animals exhibited a significantly different pattern of early gene expression in ventral tegmental area, origin of the mesolimbic-mesocortical dopamine system and in the anterior thalamic nuclei, compared with saline treated controls subjected to exactly the same recording conditions. The evidence of central nervous system excitation with clozapine may be important to the unique therapeutic effect of this atypical antipsychotic in the treatment of symptoms, especially the deficit symptoms, of schizophrenia.

Keywords:  Clozapine, Kindling, Myoclonus, Schizophrenia

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-1211(96)00061-7

Epilepsy Research
Volume 26, Issue 1 , Pages 295-304, December 1996